| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083119 | Drug Discovery Today: Therapeutic Strategies | 2006 | 8 Pages |
Abstract
Chemokines and their receptors function in leukocyte trafficking to sites of inflammation and cellular activation and are attractive therapeutic targets for immune-mediated inflammatory diseases. Developing therapeutics for this family of molecules has proved challenging. Small and large molecule therapeutics are now in development for several key receptor-ligand pairs. Neither strategy has yielded human proof of concept for intervening in this pathway; however, we are now closer than ever to realizing this goal.
Section editor:Martin Braddock – AstraZeneca R&D Charnwood, Loughborough, UK
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Anuk M. Das, Carrie M. Brodmerkel,